Dolutegravir Is the
#1 Prescribed INSTI
for HIV-1 in
the United States*

Not actual patients.

*Based on data since May 2016 from IMS Health National Prescription Audit for total prescription (TRx) volume for the most recent rolling 4 weeks across retail, mail-order, and long-term care channels. Includes any INSTI for a new prescription or refill prescription, whether part of a multi-tablet regimen or fixed-dose combination. Data are not intended to suggest comparison of safety or efficacy to any other antiretroviral agents.

INSTI=integrase strand transfer inhibitor.

Indications and Usage for TRIUMEQ and TIVICAY:

TRIUMEQ is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 40 kg.

TIVICAY, a component of TRIUMEQ, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection:

  • in adults and pediatric patients weighing at least 30 kg
  • with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent

Limitations of Use:

TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in TRIUMEQ is insufficient in these subpopulations. See full prescribing information for TIVICAY

Please see full Prescribing Information, including Boxed Warning and Medication Guide, for TRIUMEQ.

Please see full Prescribing Information for TIVICAY.